

○ KQ 2b. Do outcomes vary by patient/client (as well as parent) or clinical or organizational characteristics including the nature, extent, and timing of exposure (e.g., recent or ongoing vs. prior exposure)?

PICOTS (POPULATIONS, INTERVENTIONS, COMPARATORS, OUTCOMES, TIMING, AND SETTING)

PICOTS	KQ1	KQ2
Population .....	Adults 18 years and older, regardless of trauma exposure. 1b. Patient/client and clinical characteristics including type, time since, and duration of trauma exposure; gender; race/ethnicity; age; clinical condition; or disorder (e.g., anxiety, depression, substance use).	Youth <18 years, regardless of trauma exposure.  2b. Patient/client and clinical characteristics including type, time since, and duration of trauma exposure; gender; race/ethnicity; age; clinical condition; or disorder, (e.g., anxiety, depression, ADHD, conduct disorder, substance use).
Intervention .....	TIC models/components of care (e.g., education and training of providers about trauma, screening patients/clients for trauma exposure using ACEs or other tools, screening for symptoms, delivering point-of-care interventions, referring patients/clients for various forms of additional assessment and treatment for indicated needs). 1a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening.	TIC models/components of care (e.g., education and training of providers about trauma, screening patients/clients for trauma exposure using ACEs or other tools, screening for symptoms, delivering point of care interventions, referring patients/clients for various forms of additional assessment and treatment for indicated needs). 2a. single or multi-component, individual or group, targeting organizations, providers, patients/clients, caregivers, or a combination, training, screening.
Comparator .....	No TIC model of care/usual or routine care (CAU) ..... Other TIC model or component(s) of care, evidence-based therapies for trauma-related conditions (e.g., prolonged exposure, cognitive processing therapy) or approaches (e.g., Collaborative Care).	No TIC model of care/usual or routine care (CAU). Other TIC model or component(s) of care, evidence-based therapies for trauma-related conditions (e.g., trauma-focused CBT) or approaches (e.g., Collaborative Care).
Outcome .....	<i>Trauma-Specific:</i> Additional or repeat trauma exposure from the point-of-care in the course of care/service delivery (e.g., retraumatization). <i>Process outcomes:</i> Health care outcomes/utilization/referral, provider burnout/mental health. <i>Organizational/practice/systems outcomes:</i> Intake and referral processes (e.g., wait times), disseminated policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity. <i>Patient/client-centered outcomes:</i> Physical and mental health outcomes, functioning, clinical improvement, patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of life). <i>Harms:</i> Includes displacement of evidence based care (e.g., screening for anxiety, depression, substance use, suicide risk), increase in patient/client aggression or other behavioral misconduct.	<i>Trauma-Specific:</i> Additional or repeat trauma exposure from the point-of-care in the course of care/service delivery (e.g., retraumatization). <i>Process outcomes:</i> Healthcare outcomes/utilization/referral, provider outcomes burnout/mental health. <i>Organizational/practice/systems outcomes:</i> Intake and referral processes (e.g., wait times), disseminated policies, trainings, staffing (e.g., scribes), administrative requirements, access to treatment, workforce diversity, anti-racism principles. <i>Patient/client-centered outcomes:</i> Physical and mental health outcomes, functioning, clinical improvement, patient/client engagement, trust, comfort or satisfaction, and strengths-based outcomes (e.g., quality of life). <i>Harms:</i> Includes displacement of evidence based care (e.g., screening for developmental milestones, ADHD, depression, anxiety, suicide risk, substance use), increase in patient/client aggression or other behavioral misconduct.
Timing .....	Any .....	Any.
Setting .....	Routine or emergency healthcare in any setting that provides human or social services, including in non-traditional settings (e.g., HIV clinics providing behavioral health care).	Routine or emergency healthcare in any setting that provides human or social services, including in non-traditional settings (e.g., school-based clinics providing behavioral health care).

Dated: October 27, 2023.

**Marquita Cullom,**

Associate Director.

[FR Doc. 2023-24214 Filed 11-1-23; 8:45 am]

BILLING CODE 4160-90-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92-463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)-TS24-010, Identify and Evaluate Potential Risk Factors for Amyotrophic Lateral Sclerosis (ALS).*

*Date:* April 9, 2024.

*Time:* 8:30 a.m.-5 p.m., EDT.

*Place:* Videoconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Mikel L. Walters, Ph.D., Scientific Review Officer, National Center for

Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106–9, Atlanta, Georgia 30341. Telephone: (404) 639–0913; Email: [MWalters@cdc.gov](mailto:MWalters@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–24242 Filed 11–1–23; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–CE24–030, Research Grants for Preventing Violence and Violence Related Injury (R01).*

*Dates:* April 2–3, 2024.

*Times:* 8:30 a.m.–5 p.m., EDT.

*Place:* Videoconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Carlisha Gentles, Pharm.D., B.C.P.S., C.D.C.E.S., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control

and Prevention, 4770 Buford Highway NE, Mailstop F–63, Atlanta, Georgia 30341. Telephone: (770) 488–1504; Email: [CGentles@cdc.gov](mailto:CGentles@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–24241 Filed 11–1–23; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–CE22–003, Rigorously Evaluating Programs and Policies to Prevent Child Sexual Abuse (CSA).*

*Date:* April 11, 2024.

*Time:* 8:30 a.m.–5 p.m., EDT.

*Place:* Videoconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Mikel L. Walters, Ph.D., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease and Prevention, 4770 Buford Highway NE, Mailstop S106–9, Atlanta,

Georgia 30341. Telephone: (404) 639–0913; Email: [MWalters@cdc.gov](mailto:MWalters@cdc.gov).

The Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Kalwant Smagh,**

*Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.*

[FR Doc. 2023–24239 Filed 11–1–23; 8:45 am]

**BILLING CODE 4163–18–P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

**Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–CE24–012, Rigorous Evaluation of Policy-Level Interventions to Prevent Overdose.*

*Date:* March 26, 2024.

*Time:* 8:30 a.m.–5 p.m., EDT.

*Place:* Videoconference.

*Agenda:* To review and evaluate grant applications.

*For Further Information Contact:* Aisha L. Wilkes, M.P.H., Scientific Review Officer, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S106–9, Atlanta, Georgia 30341. Telephone (404) 639–6473; Email: [AWilkes@cdc.gov](mailto:AWilkes@cdc.gov).